Dividends & Buybacks ·
NeuroSense Therapeutics Ltd. announced a reverse stock split of its ordinary shares at a ratio of 1-for-20…
NRSNNeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. announced a reverse stock split of its ordinary shares at a ratio of 1-for-20, consolidating every twenty existing shares into one new share. The effective date for trading on the Nasdaq Capital Market is September 14, 2026. This action reduces the issued and outstanding share count from approximately 37.9 million to roughly 1.9 million, with fractional shares rounded up to the nearest whole share rather than paid in cash. Outstanding warrants and options will receive proportionate adjustments to their exercise prices and share counts. The company operates in the biotechnology industry, focusing on developing therapeutic treatments for neurological disorders.